


Amuvatinib

Chemical Properties

CAS No. :	850879-09-3
Formula:	C ₂₃ H ₂₁ N ₅ O ₃ S
Molecular Weight:	447.51
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
Targets(IC50)	Apoptosis,FLT,c-RET,c-Kit,c-Met/HGFR,DNA/RNA Synthesis,PDGFR
In vitro	Tumor growth was inhibited by intraperitoneal injection of 10 mg/kg-75 mg/kg or by oral administration of 50 mg/kg-200 mg/kg MP-470 in a mouse transplantation tumor model harboring HT-29, A549, and SB-CL2 cells.The combination of 20 mg/kg MP-470 and erlotinib markedly inhibited the tumor growth in mice harboring LNCaP transplantation tumors. tumor growth in mice bearing LNCaP graft tumors.
In vivo	1 μM MP-470 inhibited tyrosine phosphorylation of AXL in MDA-MB-231 cells.10 μM MP-470 caused cell cycle arrest in the G1 phase and decreased Akt and ERK1/2 phosphorylation in LNCaP cells.10 μM MP-470 inhibited c-Met phosphorylation in SF767 cells and sensitized the cells to radiation.10 μM MP-470 combined with radiation inhibited GSK-3β activity, induced apoptosis, and disrupted dsDNA b break repair, possibly by inhibiting Rad51. 470 inhibited GSK-3β activity and induced apoptosis in combination with radiation, and disrupted dsDNA b-break repair, possibly by inhibiting Rad51. MP-470 hydrochloride effectively inhibited the proliferation of OVCAR-3, A549, NCI-H647, DMS-153, and DMS-114 cells, with an IC50 of 0.9 μM to 7.86 μM. 7.86 μM. MP-470 was toxic to MiaPaCa-2, PANC-1 and GIST882 cells with IC50s ranging from 1.6 μM to 3.0 μM. MP-470 was toxic to LNCaP and PC-3 but not to DU145 cells with IC50s of 4 μM and 8 μM, respectively, and induced apoptosis at 10 μM.
Kinase Assay	Kinase inhibition assay of c-Kit and PDGFRα: For the testing of inhibitory activity against c-Kit and PDGFRα, enzymes are incubated with varying concentrations of MP-470 and radiolabeled γ-32P-ATP. After 30 min, the reaction mixtures are electrophoresed on an acrylamide gel and autophosphorylation, quantitated by the amount of radioactivity incorporated into the enzyme, is assayed.
Cell Research	Cells are plated at a density of 2 × 10 ³ to 1 × 10 ⁴ cells per well in 100 μL medium on day 0 in 96-well Falcon microtiter plates. On day 1, ten μL of serial dilutions of MP-470 are added to the plates in quadruplicates. After incubation for 4 days, the cells are fixed with 10% Trichloroacetic acid solution. Subsequently, they are labeled with 0.04% Sulforhodamine B (SRB) in 1% acetic acid. After multiple washes to remove the excess dye, 100 μL of 50 mM Tris solution is added to each well in order to dissolve the dye. The absorbance of each well is read on a plate reader at 570 nm. Data are expressed as the

A DRUG SCREENING EXPERT

Cell Research	percentage of survival of control calculated from the absorbance corrected for background absorbance. The surviving percent of cells is determined by dividing the mean absorbance values of the monoclonal antibody by mean absorbance values of the control and multiplying by 100.(Only for Reference)
---------------	---

Solubility Information

Solubility	DMSO: 50 mg/mL (111.73 mM),Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.47 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2346 mL	11.1729 mL	22.3459 mL
5 mM	0.4469 mL	2.2346 mL	4.4692 mL
10 mM	0.2235 mL	1.1173 mL	2.2346 mL
50 mM	0.0447 mL	0.2235 mL	0.4469 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent. *Scientific Reports*. 2018 Oct 8;8(1):14969
- Hurley LH, et al. World Patent, WO/2005/037825.
- Mahadevan D, et al. *Oncogene*, 2007, 26(27), 3909-3919.
- Qi W, et al. *BMC Cancer*, 2009, 9, 142.
- Welsh JW, et al. *Radiat Oncol*, 2009, 4, 69.
- Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent[J]. *Scientific reports*. 2018 Oct 8;8(1):14969.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481